Esperion Therapeutics, Inc. (ESPR)
Company Info
Highlights
$176.91M
-$0.85
-4.78
$194.58M
$136.04M
-$67.48M
$0.73 - $3.94
$5.79
15.22%
5.60
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Esperion Therapeutics, Inc. (ESPR) returned -63.72% year-to-date (YTD) and -63.55% over the past 12 months. Over the past 10 years, ESPR returned -38.69% annually, underperforming the S&P 500 benchmark at 10.46%.
ESPR
-63.72%
-16.85%
-64.99%
-63.55%
-56.09%
-38.69%
^GSPC (Benchmark)
-3.77%
7.44%
-5.60%
8.37%
14.12%
10.46%
Monthly Returns
The table below presents the monthly returns of ESPR, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -18.64% | -5.03% | -15.29% | -30.60% | -20.13% | -63.72% | |||||||
| 2024 | -28.43% | 17.29% | 6.77% | -26.49% | 9.64% | 2.78% | 4.05% | -20.78% | -9.84% | 23.64% | 37.25% | -21.43% | -26.42% |
| 2023 | 2.09% | -2.83% | -74.27% | -16.98% | 3.03% | 2.21% | 12.95% | 1.91% | -38.75% | -15.43% | 60.47% | 124.81% | -52.01% |
| 2022 | -14.20% | -4.66% | 13.45% | 22.41% | 0.35% | 11.58% | -9.28% | 29.29% | -10.19% | 21.34% | -17.59% | -7.01% | 24.60% |
| 2021 | 21.12% | -13.02% | 2.41% | -3.92% | -26.12% | 6.23% | -27.23% | -15.40% | -7.45% | -25.81% | -2.35% | -42.73% | -80.77% |
| 2020 | -9.31% | -6.64% | -37.55% | 25.59% | 6.99% | 21.10% | -26.66% | -4.07% | 2.96% | -19.37% | -5.51% | -8.19% | -56.40% |
| 2019 | 0.98% | -0.75% | -12.91% | 7.35% | 10.44% | -2.27% | -14.68% | -7.68% | 0.05% | 8.48% | 29.14% | 16.10% | 29.63% |
| 2018 | 10.13% | 10.90% | -10.05% | -3.21% | -45.02% | 1.82% | 14.67% | 10.12% | -10.35% | 2.39% | 17.02% | -13.47% | -30.13% |
| 2017 | -3.19% | 115.92% | 34.93% | 1.25% | -10.43% | 44.53% | -2.14% | 9.12% | 1.42% | -8.74% | 34.48% | 7.04% | 425.88% |
| 2016 | -33.15% | 0.07% | 13.57% | -3.08% | 4.45% | -42.29% | 9.92% | -0.83% | 28.60% | -25.63% | 2.52% | 18.56% | -43.76% |
| 2015 | 13.50% | 36.06% | 48.28% | 2.73% | 13.01% | -23.95% | -24.17% | -22.66% | -50.80% | 1.74% | 18.38% | -21.65% | -44.96% |
| 2014 | 11.06% | 1.90% | -2.77% | -8.80% | 10.66% | 3.80% | -9.53% | 8.79% | 56.90% | 19.58% | 8.14% | 27.85% | 194.32% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of ESPR is 10, meaning it’s performing worse than 90% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Esperion Therapeutics, Inc. (ESPR) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Esperion Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Esperion Therapeutics, Inc. was 99.37%, occurring on Oct 26, 2023. The portfolio has not yet recovered.
The current Esperion Therapeutics, Inc. drawdown is 99.31%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.37% | May 20, 2015 | 2125 | Oct 26, 2023 | — | — | — |
| -41.24% | Oct 3, 2013 | 39 | Nov 26, 2013 | 209 | Sep 26, 2014 | 248 |
| -28.66% | Oct 9, 2014 | 6 | Oct 16, 2014 | 11 | Oct 31, 2014 | 17 |
| -22.6% | Mar 24, 2015 | 2 | Mar 25, 2015 | 38 | May 19, 2015 | 40 |
| -18.82% | Aug 6, 2013 | 25 | Sep 10, 2013 | 12 | Sep 26, 2013 | 37 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Esperion Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Esperion Therapeutics, Inc., comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -37.5%.
Valuation
The Valuation section provides an overview of how Esperion Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for ESPR compared to other companies in the Biotechnology industry. ESPR currently has a PEG ratio of -4.8. This PEG ratio is negative, which typically signals that the company's earnings are expected to decline. A negative PEG is not considered meaningful for valuation purposes.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for ESPR relative to other companies in the Biotechnology industry. Currently, ESPR has a P/S ratio of 0.7. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ESPR in comparison with other companies in the Biotechnology industry. Currently, ESPR has a P/B value of 98.4. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |